| Vitas Healthcare Corporation Of Florida 4450 W Eau Gallie Blvd Ste 250, Melbourne, FL, 32934 | |
| (321) 751-6671 |
News Archive
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
Trauma surgeons are often the first point of contact with the health care system for victims of violence. However, their role can extend beyond caring for a patient's physical injuries.
MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).
› Verified 6 days ago
| Name | Vitas Healthcare Corporation Of Florida |
|---|---|
| Location | 4450 W Eau Gallie Blvd Ste 250, Melbourne, Florida |
| Hospice ID | 101545 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| SSA county code | 040 |
News Archive
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
Trauma surgeons are often the first point of contact with the health care system for victims of violence. However, their role can extend beyond caring for a patient's physical injuries.
MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).
› Verified 6 days ago
| NPI Number | 1669548053 |
| Organization Name | Vitas Healthcare Corporation Of Florida |
| Address | 4450 W Eau Gallie Blvd Melbourne, Florida, 32934 |
| Phone Number | (321)751-6671 |
News Archive
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
Trauma surgeons are often the first point of contact with the health care system for victims of violence. However, their role can extend beyond caring for a patient's physical injuries.
MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).
› Verified 6 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 92.2 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 89.3 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 79.4 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 62.2 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 92.1 | 97.3 |
| Patients who got timely treatment for shortness of breath | 94.9 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 94.0 | 93.3 |
News Archive
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
Trauma surgeons are often the first point of contact with the health care system for victims of violence. However, their role can extend beyond caring for a patient's physical injuries.
MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).
› Verified 6 days ago
| Home Health Aides | 480 |
| Counselors | 64 |
| Licensed Practical or Vocational Nurses | 279 |
| Medical Social Workers | 69 |
| Physicians | 53 |
| Registered Nurses | 509 |
| Total Employees | 1454 |
|---|
News Archive
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
Trauma surgeons are often the first point of contact with the health care system for victims of violence. However, their role can extend beyond caring for a patient's physical injuries.
MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).
› Verified 6 days ago
| Others | 482 |
| Total Volunteers | 482 |
|---|
News Archive
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
Trauma surgeons are often the first point of contact with the health care system for victims of violence. However, their role can extend beyond caring for a patient's physical injuries.
MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib).
› Verified 6 days ago
| Vitas Healthcare Corporation Of Florida Location: 4450 W Eau Gallie Blvd Ste 250, Melbourne, Florida, 32934 Phone: (321) 751-6671 |